Oligometastatic non-small cell lung cancer: a narrative review of stereotactic ablative radiotherapy

Dohopolski, Michael; Iyengar, Puneeth

doi:10.21037/apm-20-1409

Cited by 8 publications

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many of these are aiming to demonstrate the benefit in OS of the addition of SABR to systemic therapy. Moreover, the OMEGA (NCT03827577) study is comparing locally ablative treatment vs conventional systemic therapy ( 41 ).…”

Section: Sabr In Metastatic Nsclcmentioning

confidence: 99%

Stereotactic ablative radiotherapy for acquired resistance to EGFR therapy in metastatic non-small cell lung cancer

Chicas-Sett¹,

Martínez²,

Blanquisett³

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

The advent of targeted therapy has transformed the treatment paradigm and survival of patients with metastatic non-small cell lung cancer (NSCLC) with driver mutations. The development of acquired resistances during treatment with tyrosine kinase inhibitors (TKIs) impedes a prolonged survival in many patients. This fact is leading to the use of locally ablative therapies such as stereotactic ablative radiotherapy (SABR) to counter these resistances. SABR is a non-invasive treatment that can be delivered in multiple locations and has already proven effective in oligometastatic disease. Clinical evidence suggests that the combination of SABR with TKIs prolongs progression-free survival (PFS) in metastatic NSCLC patients with mutations in epidermal growth factor receptor (EGFR), with international guidelines recommending their use in unfavorable scenarios such as oligoprogressive disease. In this publication, we have reviewed the available evidence on EGFR-TKIs resistance mechanisms and the combination of SABR with TKI in metastatic NSCLC with EGFR mutations. We also describe the utility and clinical recommendations of this combination in oligometastatic and oligoprogressive disease.

show abstract

Section: Sabr In Metastatic Nsclcmentioning

confidence: 99%

Stereotactic ablative radiotherapy for acquired resistance to EGFR therapy in metastatic non-small cell lung cancer

Chicas-Sett¹,

Martínez²,

Blanquisett³

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Lung cancer is the third most common malignant tumor in humans and the leading cause of cancer-related mortality worldwide (1,2). Patients with non-small cell lung cancer (NSCLC) are more likely to die from the disease than those with small-cell lung carcinoma (3)(4)(5). NSCLC patients who are diagnosed during advanced stages typically have mild symptoms that are difficult to detect.…”

Section: Introductionmentioning

confidence: 99%

Integrated analysis reveals the microenvironment of non-small cell lung cancer and a macrophage-related prognostic model

Xie¹,

Huang²,

Qian³

et al. 2023

Transl Lung Cancer Res

View full text Add to dashboard Cite

Background: In the treatment of non-small cell lung cancer (NSCLC), recent advances in immunotherapy have heralded a new era. Despite the success of immune therapy, a subset of patients persistently fails to respond. Therefore, to better improve the efficacy of immunotherapy and achieve the purpose of precision therapy, the research and exploration of tumor immunotherapy biomarkers have received much attention.Methods: Single-cell transcriptomic profiling was used to reveal tumor heterogeneity and the microenvironment in NSCLC. The Cell-type Identification by Estimating Relative Subsets of RNA Transcripts (CIBERSORT) algorithm was utilized to speculate the relative fractions of 22 infiltration immunocyte types in NSCLC. Univariate Cox and least absolute shrinkage and selection operator (LASSO) regression analyses were used for the construction of risk prognostic models and predictive nomograms of NSCLC. Spearman's correlation analysis was employed to explore the relationship between risk score and tumor mutation burden (TMB) and immune checkpoint inhibitors (ICIs). Screening of chemotherapeutic agents in the high-and low-risk groups was performed with the "pRRophetic" package in R. Intercellular communication analysis was conducted using the "CellChat" package.Results: We found that most tumor-infiltrating immune cells were T cells and monocytes. We also found that there was a significant difference in the tumor-infiltrating immune cells and ICIs across different molecular subtypes. Further analysis showed that M0 and M1 mononuclear macrophages were significantly different in different molecular subtypes. The risk prediction model was shown to have to ability to accurately predict the prognosis, immune cell infiltration, and chemotherapy efficacy of patients in the high and low-risk groups. Finally, we found that the carcinogenic effect of migration inhibitory factor (MIF) is mediated by binding to CD74, CXCR4, and CD44 receptors involved in MIF cell signaling. Conclusions:We have revealed the tumor microenvironment (TME) of NSCLC through single-cell data analysis and constructed a prognosis model of macrophage-related genes. These results could provide new therapeutic targets for NSCLC.

show abstract

Recent advances in lung cancer research: unravelling the future of treatment

Bertolaccini,

Casiraghi,

Uslenghi

et al. 2024

Updates Surg

View full text Add to dashboard Cite

Oligometastatic non-small cell lung cancer: a narrative review of stereotactic ablative radiotherapy

Cited by 8 publications

References 30 publications

Stereotactic ablative radiotherapy for acquired resistance to EGFR therapy in metastatic non-small cell lung cancer

Stereotactic ablative radiotherapy for acquired resistance to EGFR therapy in metastatic non-small cell lung cancer

Integrated analysis reveals the microenvironment of non-small cell lung cancer and a macrophage-related prognostic model

Recent advances in lung cancer research: unravelling the future of treatment

Contact Info

Product

Resources

About